Coya Therapeutics, Inc. (COYA)
Market Cap | 111.88M |
Revenue (ttm) | 6.13M |
Net Income (ttm) | -10.30M |
Shares Out | 15.22M |
EPS (ttm) | -0.85 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 41,855 |
Open | 7.49 |
Previous Close | 7.36 |
Day's Range | 7.21 - 7.55 |
52-Week Range | 3.21 - 10.69 |
Beta | n/a |
Analysts | Strong Buy |
Price Target | 16.00 (+117.69%) |
Earnings Date | Aug 6, 2024 |
About COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company’s product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company’s product... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for COYA stock is "Strong Buy." The 12-month stock price forecast is $16.0, which is an increase of 117.69% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/p/a/press13-2487845.jpg)
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
![](https://cdn.snapi.dev/images/v1/4/e/press12-2473145.jpg)
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) func...
![](https://cdn.snapi.dev/images/v1/h/n/press13-2458866.jpg)
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) func...
![](https://cdn.snapi.dev/images/v1/q/j/press2-2449694.jpg)
Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
Coya Therapeutics (COYA) CEO on $5M Alzheimer's Drug Discovery Foundation Investment
Coya Therapeutics (COYA) is a clinical-stage company focused on developing multi-modality Treg therapies. CEO Howard Berman joins Nicole Petallides to give an overview of the company.
![](https://cdn.snapi.dev/images/v1/t/x/press14-2443280.jpg)
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
![](https://cdn.snapi.dev/images/v1/b/d/press13-2439507.jpg)
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
![](https://cdn.snapi.dev/images/v1/6/w/press4-2422650.jpg)
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
![](https://cdn.snapi.dev/images/v1/x/w/press3-2394033.jpg)
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
![](https://cdn.snapi.dev/images/v1/g/7/press5-2382930.jpg)
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
![](https://cdn.snapi.dev/images/v1/w/4/press19-2378020.jpg)
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
![](https://cdn.snapi.dev/images/v1/n/a/conf16-2360832.jpg)
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
![](https://cdn.snapi.dev/images/v1/g/u/press19-2330880.jpg)
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
![](https://cdn.snapi.dev/images/v1/f/m/press12-2320120.jpg)
Coya Therapeutics to Participate in BTIG Fireside Discussion
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
![](https://cdn.snapi.dev/images/v1/l/8/press16-2319821.jpg)
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
![](https://cdn.snapi.dev/images/v1/c/7/press7-2310776.jpg)
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics primarily focused on the restoration of regulatory T cell (Treg...
![](https://cdn.snapi.dev/images/v1/a/a/conf3-2301007.jpg)
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
HOUSTON--(BUSINESS WIRE)---- $COYA #ADPD--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T...
![](https://cdn.snapi.dev/images/v1/l/c/conf19-2288413.jpg)
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
![](https://cdn.snapi.dev/images/v1/x/y/press18-2285867.jpg)
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer's Disease and Coya's Pathway to a “Pipeline in a Product”
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance regulato...
![](https://cdn.snapi.dev/images/v1/c/a/press19-2273356.jpg)
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance regulato...
![](https://cdn.snapi.dev/images/v1/u/z/press9-2248613.jpg)
Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
![](https://cdn.snapi.dev/images/v1/r/m/press14-2234284.jpg)
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces tha...
![](https://cdn.snapi.dev/images/v1/q/9/press12-2230397.jpg)
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson's Disease in Addition to Amyotrophic Lateral Sclerosis
HOUSTON--(BUSINESS WIRE)---- $COYA #ALS--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function...
![](https://cdn.snapi.dev/images/v1/w/i/press8-2218014.jpg)
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (“Coya”), a clinical-stage biotechnology company today announced successful meetings with the U.S. Food and Drug Administration (FDA) following a pre-...
![](https://cdn.snapi.dev/images/v1/i/p/press6-2203453.jpg)
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the funct...